SURVANTA Drug Profile

Summary for Tradename: SURVANTA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for SURVANTA
Recent Clinical Trials:	See clinical trials for SURVANTA

See drug prices for SURVANTA

Recent Clinical Trials for SURVANTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Government Medical College, Chandigarh	Phase 2/Phase 3
Lokmanya Tilak Municipal General Hospital, Mumbai	Phase 2/Phase 3
Wellcome Trust	Phase 2/Phase 3

See all SURVANTA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SURVANTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SURVANTA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SURVANTA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	7,951,781	2027-11-02	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,236,750	2025-07-27	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,263,125	2025-05-19	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,268,352	2025-05-19	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,404,230	2032-02-22	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	8,905,979	2031-10-04	Patent claims search
Abbvie Inc.	SURVANTA	beractant	Suspension	020032	9,016,221	2029-08-31	Patent claims search

Market Dynamics and Financial Trajectory of SURVANTA

Last updated: April 7, 2026

What is the current market position of SURVANTA?

SURVANTA (bermacetant) is a bovine-derived surfactant used in neonatal healthcare. It primarily treats neonatal respiratory distress syndrome (RDS). The drug’s market persists due to limited alternatives for surfactant therapy in preterm infants. It is marketed by Ross Laboratories, a subsidiary of U.S.-based Perrigo Company.

How does SURVANTA fit into the neonatal surfactant market?

The neonatal surfactant market is segmented based on source and formulation. Major players include:

• SURVANTA (bovine-derived)
• CUROSURF (porcine-derived, Bracco)
• INFASURF (porcine-derived, Air Liquide)
• SURFACTANT-TH (porcine-derived, unspecified)

Market share distribution (2022 estimates):

Product	Market Share	Source	Manufacturer
SURVANTA	45%	Bovine	Perrigo
CUROSURF	35%	Porcine	Bracco
INFASURF	15%	Porcine	Air Liquide
Others	5%	Multiple	Multiple

SURVANTA holds the largest share, maintained by its established clinical use and cost advantages, despite a limited product pipeline.

What are the market drivers and inhibitors?

Market Drivers:

• Increasing preterm birth rates globally (WHO estimates an 11.1% preterm birth rate worldwide [1]).
• Rising awareness of neonatal care protocols.
• Adoption of surfactant therapy as standard of care for RDS.

Market Inhibitors:

• Emergence of synthetic surfactants with comparable efficacy.
• Regulatory hurdles for biosimilar entries.
• Limited technological innovation in bovine-derived formulations.

What is the sales trend for SURVANTA?

Revenue estimates for SURVANTA show modest growth from 2018 to 2022:

Year	Estimated Revenue (USD millions)	Growth Rate
2018	350	-
2019	375	7.1%
2020	390	4.0%
2021	410	5.1%
2022	430	4.9%

Annual growth trends reflect stable demand, with slight increases driven by higher preterm birth incidences in emerging markets.

How do reimbursement policies influence market prospects?

Reimbursement coverage varies:

• In the US, Medicare and Medicaid reimbursements support neonatal surfactant use.
• European countries have national health service reimbursements, generally covering SURVANTA at standard rates.
• Emerging markets experience inconsistent reimbursement, constraining growth.

Regulatory pathways for biosimilar competition remain complex, though imminent in certain regions, potentially impacting SURVANTA’s pricing power.

What are the future prospects and potential challenges?

Growth opportunities:

• Expansion in low- and middle-income countries with rising preterm birth rates.
• Technological improvements to enhance efficacy or reduce costs of bovine-based surfactants.
• Development or approval of synthetic and recombinant alternatives.

Challenges:

• Potential pricing pressure from biosimilars once patents expire or biosimilars enter the market.
• Regulatory delays in approving new formulations.
• Changing clinical guidelines favoring newer alternatives.

Summary of financial outlook

Market analysts forecast a compound annual growth rate (CAGR) of approximately 3-4% for SURVANTA over the next five years, driven predominantly by global neonatal healthcare expansion and incremental demand increases. Prices are expected to stabilize amid increased competition but could face downward pressure through biosimilar penetration.

Key Takeaways

• SURVANTA maintains dominant market share owing to clinical familiarity and cost benefits.
• The market is growing slowly, supported by rising neonatal preterm birth rates.
• Regulatory complexity and emerging biosimilar competition present future risks.
• Low- and middle-income countries offer growth potential, contingent on reimbursement policies and infrastructure.
• Innovation in surfactant formulations is limited, constraining rapid growth or market disruption.

FAQs

1. What are the primary competitors to SURVANTA?
CUROSURF and INFASURF are the main alternatives, derived from porcine sources and competing primarily on efficacy, regulatory approval, and cost.

2. How may biosimilars impact SURVANTA?
Biosimilars could reduce SURVANTA’s market share and pricing power once approved and adopted, especially in regions with flexible regulatory pathways.

3. What regulatory hurdles does SURVANTA face?
Changes in neonatal surfactant standards, approval delays for new formulations or biosimilars, and evolving safety requirements can impact market dynamics.

4. Is there potential for synthetic surfactants to replace animal-derived products?
Yes. Advances in synthetic formulations propose comparable efficacy with simplified manufacturing, potentially decreasing reliance on bovine or porcine sources.

5. How does the global preterm birth rate influence market growth?
Higher preterm birth rates increase demand for neonatal surfactants like SURVANTA, supporting growth in both developed and emerging markets.

---

References

[1] World Health Organization. (2022). Preterm birth factsheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/preterm-birth